Sinotherapeutics (688247) Stock Overview
A specialty pharmaceutical company, research, develops, manufactures, and commercializes generic and formulation products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
688247 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Sinotherapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥7.26 |
| 52 Week High | CN¥13.28 |
| 52 Week Low | CN¥7.19 |
| Beta | 0.099 |
| 1 Month Change | -14.69% |
| 3 Month Change | -23.42% |
| 1 Year Change | -28.47% |
| 3 Year Change | -43.06% |
| 5 Year Change | n/a |
| Change since IPO | -46.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688247 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -4.2% | 2.3% | 1.0% |
| 1Y | -28.5% | -11.1% | 32.3% |
Return vs Industry: 688247 underperformed the CN Pharmaceuticals industry which returned -11.1% over the past year.
Return vs Market: 688247 underperformed the CN Market which returned 32.3% over the past year.
Price Volatility
| 688247 volatility | |
|---|---|
| 688247 Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in CN Market | 10.6% |
| 10% least volatile stocks in CN Market | 4.0% |
Stable Share Price: 688247 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688247's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 319 | Ming Jie Guo | www.sinotph.com |
Sinotherapeutics Inc., a specialty pharmaceutical company, research, develops, manufactures, and commercializes generic and formulation products in China. The company’s products are indicated for infection, oncology and rheumatology, gastroenterology and metabolism, neurology, cardiology, and nephrology. It offers posaconazole delayed-release tablets; olaparib, exemestane, and tofacitinib extended-release tablets; and mesalamine delayed-release, dapagliflozin and metformin hydrochloride sustained-release, sitagliptin and metformin hydrochloride sustained-release tablets, and ursodeoxycholic ACID Capsules.
Sinotherapeutics Inc. Fundamentals Summary
| 688247 fundamental statistics | |
|---|---|
| Market cap | CN¥3.39b |
| Earnings (TTM) | CN¥43.56m |
| Revenue (TTM) | CN¥432.19m |
Is 688247 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688247 income statement (TTM) | |
|---|---|
| Revenue | CN¥432.19m |
| Cost of Revenue | CN¥278.24m |
| Gross Profit | CN¥153.95m |
| Other Expenses | CN¥110.39m |
| Earnings | CN¥43.56m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.097 |
| Gross Margin | 35.62% |
| Net Profit Margin | 10.08% |
| Debt/Equity Ratio | 0% |
How did 688247 perform over the long term?
See historical performance and comparisonDividends
Does 688247 pay a reliable dividends?
See 688247 dividend history and benchmarks| Sinotherapeutics dividend dates | |
|---|---|
| Ex Dividend Date | Jun 26 2026 |
| Dividend Pay Date | Jun 26 2026 |
| Days until Ex dividend | 0 days |
| Days until Dividend pay date | 0 days |
Does 688247 pay a reliable dividends?
See 688247 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/26 11:46 |
| End of Day Share Price | 2026/06/26 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sinotherapeutics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.